SCHEMBL10072944

SCHEMBL10072944

CC(C)[C@@H]1CC[C@@H](C)C[C@H]1C(=O)Nc1cccc(F)c1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 4/20 0.61
ALDH1A1 P00352 1/20 0.51
POLB P06746 1/20 0.51
HTT P42858 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
EPHX1 P07099 1/20 0.45
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
GAA P10253 1/20 0.43
HSD17B10 Q99714 1/20 0.43
USP2 O75604 1/20 0.43
MTOR P42345 1/20 0.43
TRPV1 Q8NER1 1/20 0.42
ATM Q13315 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15133466 0.87 TRPM8 (0.62) TRPM8ALDH1A1POLBEPHX1NPC1
SCHEMBL2628762 0.87 TRPM8 (0.62) TRPM8ALDH1A1POLBHTTEPHX1
SCHEMBL2628752 0.86 TRPM8 (0.61) TRPM8ALDH1A1TDP1EPHX1MEN1
SCHEMBL4820314 0.85 TRPM8 (0.73) TRPM8POLBEPHX1MEN1KMT2A
SCHEMBL14593913 0.85 TRPM8 (0.73) TRPM8POLBEPHX1MEN1KMT2A
SCHEMBL2628777 0.85 TRPM8 (0.73) TRPM8POLBEPHX1MEN1KMT2A
SCHEMBL4817890 0.85 TRPM8 (0.73) TRPM8POLBTDP1EPHX1MEN1
SCHEMBL10073491 0.85 TRPM8 (0.73) TRPM8POLBTDP1EPHX1MEN1
SCHEMBL4143429 0.85 TRPM8 (0.60) TRPM8EPHX1HSD17B10TRPV1
SCHEMBL12835475 0.84 ALDH1A1 (0.64) ALDH1A1POLBHTTTDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1656144-B2 TRP-P8 ACTIVE COMPOUNDS AND THERAPEUTIC TREATMENT METHODS GENENTECH INC (US) 2017-12-20 EP disclosed
US-20120045448-A1 TRP-P8 ACTIVE COMPOUNDS AND THERAPEUTIC TREATMENT METHODS GENENTECH, INC. (US) 2012-02-23 US disclosed
US-7893072-B2 Cool-genic compounds as anticarcinogenic agents promoting apoptosis and inhibit angiogenesis; antiproliferative agents GENENTECH, INC. (US) 2011-02-22 US disclosed
US-7893072-B2 Cool-genic compounds as anticarcinogenic agents promoting apoptosis and inhibit angiogenesis; antiproliferative agents GENENTECH, INC. (US) 2011-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120045448-A1 TRP-P8 ACTIVE COMPOUNDS AND THERAPEUTIC TREATMENT METHODS TSG101, TP53, BAX TRPM8 28/4885ALDH1A1 3429/4885POLB 3043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.